🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Walgreens maintains Buy rating and $16 target from TD Cowen

Published 10/16/2024, 02:44 AM
WBA
-

On Tuesday, TD Cowen maintained its Buy rating and $16.00 price target for Walgreens Boots Alliance (NASDAQ:WBA), emphasizing the company's proactive measures in addressing key concerns. The firm highlighted the positive impact of Walgreens' store closure plan and the anticipated $100 million benefit to adjusted operating income (AOI) by fiscal year 2025. The analyst pointed out that the cash requirements estimated at approximately $160 million to cover potential negative free cash flow (FCF) in FY25 are lower than many had anticipated. TD Cowen also noted that Walgreens has other assets and a revolving credit facility that could cover short-term cash needs.

Walgreens' recent actions have been received favorably by the market, as reflected in the stock's performance today. The company has been focusing on strategic store closures to streamline operations and improve financial stability. These measures are part of a broader plan to optimize the company's retail footprint and enhance profitability in the long run.

According to TD Cowen, the benefits of these closures are significant. By fiscal year 2025, Walgreens is expected to see a substantial boost to its AOI, which is a key indicator of the company's operating performance excluding one-time items and certain non-cash expenses. This projected improvement is seen as a direct result of the company's current strategic initiatives.

In addition to the store closure strategy, TD Cowen addressed the concerns regarding Walgreens' cash flow. The analyst's estimation of the cash needed to offset a potential shortfall in FY25 free cash flow is lower than what was previously assumed by many in the market. This suggests that Walgreens is in a better position to manage its finances without significant strain.

Furthermore, TD Cowen reassured investors that Walgreens has access to other assets and a revolving credit facility, which could be utilized to meet short-term cash requirements if necessary. This financial flexibility is an important aspect of the company's overall financial health and its ability to navigate through challenging market conditions.

In other recent news, Walgreens Boots Alliance has announced plans to close approximately 1,200 underperforming stores over the next three years, a strategy aimed at stabilizing operations amid challenging market conditions. The company reported a decline in adjusted earnings per share (EPS) for the fourth quarter of 2024, with a 41% year-over-year decrease to $0.39. Full-year adjusted EPS also saw a 28% decline to stand at $2.88. Despite these financial challenges, the company's cost-cutting achievements exceeded $1 billion and net debt was reduced by $1.9 billion in fiscal 2024.

The company's fiscal 2025 adjusted EPS guidance is set between $1.40 and $1.80, and it anticipates a $150 million reduction in capital expenditures. Walgreens is also targeting $500 million in working capital initiatives for fiscal 2025, expecting to generate approximately $500 million in free cash flow. Despite a net loss of $8.6 billion in GAAP results, the U.S. Retail Pharmacy segment saw comparable sales rise by 8.3%, and the US Healthcare segment exceeded expectations with $66 million in adjusted EBITDA.

InvestingPro Insights

Recent InvestingPro data provides additional context to TD Cowen's analysis of Walgreens Boots Alliance (WBA). The company's market capitalization stands at $8.75 billion, reflecting its current market valuation. Despite the challenges highlighted in the article, WBA's revenue for the last twelve months as of Q3 2024 reached $145.53 billion, with a notable revenue growth of 6.92% over the same period.

An InvestingPro Tip suggests that WBA's stock is trading at a low Price to Book ratio of 0.57, indicating it may be undervalued relative to its book value. This aligns with TD Cowen's maintained Buy rating and could support the potential upside suggested by their $16.00 price target.

Another relevant InvestingPro Tip points out that WBA has a high dividend yield of 11.11%. While this may be attractive to income-focused investors, it's important to note that the dividend growth rate has declined by 47.92% over the last twelve months, which could be related to the cash flow concerns mentioned in the article.

For readers interested in a more comprehensive analysis, InvestingPro offers additional tips and insights that could further inform investment decisions regarding Walgreens Boots Alliance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.